Jose A. Alvarez-Cardona

Oct 1, 2024 | radcliffecardiology.com | Jose A. Alvarez-Cardona |Dan Lenihan |Joe Carver

Overview Join Dr Rohan Bhandari (Washington University, St Louis, US), Dr Jose Alvarez-Cardona (New York University School of Medicine, US), Dr Dan Lenihan (Saint Francis Healthcare System, US) and Dr Joe Carver (University of Pennsylvania, US) for this month's Journal Club where faculty will tackle critical research in the developing field of cardio-oncology. Learn about the safety and tolerability profiles of Zanubrutinib and Ibrutinib in patients with B-cell malignancies.

Aug 30, 2024 | healio.com | Erik Swain |Richard Smith |Jose A. Alvarez-Cardona

Jose A. Alvarez-Cardona, MD, FACC, FHFSA, FICOS Vutrisiran is an RNA interference therapeutic that is administered subcutaneously every 3 months and is currently FDA approved for the treatment of hereditary ATTR polyneuropathy. In contrast, tafamidis is an oral TTR stabilizer that is currently FDA approved for the treatment of wild-type or hereditary ATTR cardiomyopathy. The results of this study highlight the importance of early diagnosis and initiating treatment as soon as possible.

Jul 26, 2024 | radcliffecardiology.com | Jose A. Alvarez-Cardona |Kamari Ositelu |Anjali Rao |Dan Lenihan

Overview Join Dr Jose Alvarez-Cardona (New York University School of Medicine, US), Dr Kamari Ositelu (Northwestern University, US), Dr Anjali Rao (Northwestern University, US), Prof Dan Lenihan (Saint Francis Healthcare System, US) and Prof Joe Carver (University of Pennsylvania, US) as they discuss cardiac health in cancer patients. Explore the prevalence and risks of myocardial infarction in cancer patients and gain insights into the latest research and clinical findings.